Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
101.81
223
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Operating Margin
Sichuan Biokin Pharmaceutical Co Ltd
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | CN |
| Market Cap | 87.9B CNY |
| Operating Margin |
74%
|
| Country | JP |
| Market Cap | 776 550.9T JPY |
| Operating Margin |
-83%
|
| Country | US |
| Market Cap | 749.7B USD |
| Operating Margin |
35%
|
| Country | UK |
| Market Cap | 440.4B GBP |
| Operating Margin |
3%
|
| Country | DK |
| Market Cap | 3.3T DKK |
| Operating Margin |
44%
|
| Country | US |
| Market Cap | 372B USD |
| Operating Margin |
28%
|
| Country | US |
| Market Cap | 257.3B USD |
| Operating Margin |
34%
|
| Country | CH |
| Market Cap | 200.6B CHF |
| Operating Margin |
32%
|
| Country | UK |
| Market Cap | 162.5B GBP |
| Operating Margin |
21%
|
| Country | CH |
| Market Cap | 179.9B CHF |
| Operating Margin |
31%
|
| Country | US |
| Market Cap | 146B USD |
| Operating Margin |
22%
|
Sichuan Biokin Pharmaceutical Co Ltd
Glance View
Sichuan Biokin Pharmaceutical Co., Ltd. is an emerging player in the pharmaceutical landscape of China, specializing in the research, development, and manufacturing of innovative biopharmaceuticals. Founded in 2003, the company has established itself as a key contributor to the advancement of biotechnology, focusing on high-quality biosimilars and innovative drugs that address unmet medical needs. With a commitment to rigorous R&D and a collaborative approach to partnerships, including collaborations with internationally recognized institutions, Biokin is poised to enhance its product pipeline significantly. The company’s strong emphasis on biologic therapies positions it favorably within the industry, tapping into the growing global demand for effective, complex therapeutics that target various chronic and rare diseases. For investors, Sichuan Biokin represents a compelling opportunity due to its strategic positioning in a rapidly growing market segment that benefits from favorable governmental support for biotechnology innovation. As China's healthcare sector continues to expand, driven by an aging population and increasing investment in healthcare technology, Biokin’s strong foothold in biosimilars and the growing pipeline of innovative therapies suggest considerable future growth potential. Additionally, the company’s focus on adhering to international quality standards and gaining regulatory approvals could open doors to expand its market reach beyond China, enhancing long-term shareholder value. With a solid foundation in biotechnology and an ambitious vision for expansion, Sichuan Biokin is a company worth watching for investors looking to capitalize on the evolving pharmaceutical industry.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Sichuan Biokin Pharmaceutical Co Ltd's most recent financial statements, the company has Operating Margin of 74.4%.
You don't have any saved screeners yet
